Guizheng Wei

Keywords osteoarthritis semaglutide obesity metabolic reprogramming GLP-1R AMPK Introduction According to the World Health Organization, approximately 7% of the global population lives with osteoarthritis (OA),1 with the prevalence rising to 73% among the elderly (≥55 years).2 OA is widely recognized as a degenerative joint disease marked by the progressive breakdown of joint cartilage, leading to subchondral bone damage, persistent pain, and disability.

Keywords osteoarthritis semaglutide obesity metabolic reprogramming GLP-1R AMPK Get full text access Log in, subscribe or purchase for full access. References 1. Global Burden of Disease Collaborative Network (2020). Global Burden of Disease Study 2019 (GBD 2019) results. https://ghdx.healthdata.org/gbd-2019. 3. Tong, L.P. ∙ Yu, H. ∙ Huang, X.Y. ... Current understanding of osteoarthritis pathogenesis and relevant new approaches Bone Res. 2022; 10, 60 4.

Abstract Although aging has traditionally been viewed as the most important risk factor for osteoarthritis (OA), an increasing amount of epidemiological evidence has highlighted the association between metabolic abnormalities and OA, particularly in younger individuals.